Stanford launches study to better understand rare blistering skin disease
NCT ID NCT01019148
First seen May 05, 2026 · Last updated Jun 21, 2026 · Updated 8 times
Summary
This study is screening people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disease that causes painful blisters and open wounds from minor skin contact. Researchers at Stanford want to learn more about the disease and the patients' cells to develop new treatment strategies. The goal is to identify who might be eligible for future treatment studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University School of Medicine
RECRUITINGStanford, California, 94305, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.